Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02885766 | Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene | unknown | Phase 1 / Phase 2 | 65 | Fusion Pharma LLCINDUSTRY |
| 1 |
| Feb 17, 2020 |
| clinicaltrials |
| NCT02918747 | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage | unknown | Phase 2 | 100 | Hunan Cancer HospitalOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT02267915 | Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT(MAN2) | unknown | Phase 2 | 36 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04206943 | Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL(ISIKOK-19) | unknown | Phase 1 / Phase 2 | 24 | Acibadem UniversityOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02272478 | Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations(AML18) | unknown | Phase 2 / Phase 3 | 1,600 | Cardiff UniversityOTHER | 2 | Jan 23, 2020 | clinicaltrials |
| NCT04239170 | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 84 | Peking UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT02605460 | Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission | unknown | Phase 2 | 20 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03339700 | Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia | unknown | Phase 2 | 15 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04228393 | The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China | unknown | Phase 2 / Phase 3 | 82 | Wei ZhaoOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03977103 | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT | unknown | Phase 2 | 80 | University Of PerugiaOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04216771 | Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients | unknown | Phase 2 / Phase 3 | 320 | Fujian Medical UniversityOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT04163575 | Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 / Phase 2 | 100 | Kecellitics Biotech Company LtdINDUSTRY | 0 | Dec 23, 2019 | clinicaltrials |
| NCT02856048 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer(PRESOV) | unknown | Phase 2 / Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT04196205 | Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04023916 | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 11, 2019 | clinicaltrials |
| NCT02268370 | Treatment-free Remission Accomplished With Dasatinib in Patients With CML(TRAD) | unknown | Phase 2 | 131 | University Health Network, TorontoOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT02828878 | Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 12 | Cellect BiotechnologyINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
| NCT03527628 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy((Optimist)) | unknown | Phase 2 | 220 | King Abdullah International Medical Research CenterOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04162119 | Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04163302 | Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT02619630 | Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)(GRAALL-2014/T) | unknown | Phase 2 | 275 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02809092 | Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 30 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT03746223 | Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT02060656 | Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)(LEGEND) | unknown | Phase 2 | 92 | Royal Marsden NHS Foundation TrustOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT03497533 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19(Trident19-H) | unknown | Phase 1 / Phase 2 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT04066920 | IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL | unknown | Phase 2 | 30 | Deok-Hwan YangOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT04065308 | Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma(Dara_DCEP) | unknown | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT04063189 | Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | unknown | Phase 2 | 100 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT03181815 | Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03318419 | Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT04061772 | A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma | unknown | Phase 2 | 54 | Zhejiang Cancer HospitalOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03598179 | XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects | unknown | Phase 2 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04021992 | GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT04043676 | Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia | unknown | Phase 2 | 40 | Fundación Teófilo Hernando, SpainOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT02495415 | Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas | unknown | Phase 2 | 140 | CerRx, Inc.INDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03913312 | Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML | unknown | Phase 1 / Phase 2 | 150 | Ruijin HospitalOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04026269 | Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen | unknown | Phase 1 / Phase 2 | 30 | Han weidongOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04015024 | A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03715309 | R2 in the Treatment of Follicular Lymphoma | unknown | Phase 2 | 115 | Ruijin HospitalOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02349698 | A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02710149 | A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02935153 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02937103 | A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02954445 | A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02958410 | A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 25, 2020source: clinicaltrials